Morgan Stanley Akebia Therapeutics, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 4,315,201 shares of AKBA stock, worth $7.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,315,201

Previous 5,339,654 19.19%

Holding current value

$7.34 Million

Previous $19.4 Million 40.05%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$2.7 - $4.01 $2.77 Million - $4.11 Million	-1,024,453 Reduced 19.19%	4,315,201 $11.7 Million
Q2 2025 Aug 15, 2025	BUY	$1.55 - $3.97 $4.12 Million - $10.6 Million	2,658,456 Added 99.15%	5,339,654 $19.4 Million
Q1 2025 May 15, 2025	BUY	$1.69 - $2.84 $1.51 Million - $2.53 Million	891,147 Added 49.78%	2,681,198 $5.15 Million
Q4 2024 Feb 14, 2025	BUY	$1.26 - $2.13 $883,460 - $1.49 Million	701,159 Added 64.39%	1,790,051 $3.33 Million
Q3 2024 May 14, 2025	BUY	$0.94 - $1.55 $306,026 - $504,618	325,560 Added 42.65%	1,088,892 $1.44 Million

Q3 2024 Nov 14, 2024	BUY	$0.94 - $1.55 $306,026 - $504,618	325,560 Added 42.65%	1,088,892 $1.44 Million
Q2 2024 May 14, 2025	SELL	$0.86 - $1.63 $882,978 - $1.67 Million	-1,026,719 Reduced 57.36%	763,332 $778,000
Q2 2024 Oct 17, 2024	SELL	$0.86 - $1.63 $21,536 - $40,820	-25,043 Reduced 3.18%	763,332 $778,000
Q2 2024 Aug 14, 2024	SELL	$0.86 - $1.63 $21,536 - $40,820	-25,043 Reduced 3.18%	763,332 $778,000
Q1 2024 Oct 17, 2024	BUY	$1.27 - $2.24 $31,804 - $56,096	25,043 Added 3.28%	788,375 $1.44 Million
Q1 2024 Aug 16, 2024	BUY	$1.27 - $2.24 $145,536 - $256,695	114,596 Added 17.01%	788,375 $1.44 Million
Q1 2024 May 15, 2024	BUY	$1.27 - $2.24 $145,536 - $256,695	114,596 Added 17.01%	788,375 $1.44 Million
Q4 2023 Aug 16, 2024	SELL	$0.8 - $1.28 $71,642 - $114,627	-89,553 Reduced 11.73%	673,779 $835,000
Q4 2023 Feb 13, 2024	BUY	$0.8 - $1.28 $209,560 - $335,296	261,950 Added 63.61%	673,779 $835,000
Q3 2023 Nov 15, 2023	BUY	$0.87 - $1.84 $32,368 - $68,457	37,205 Added 9.93%	411,829 $469,000
Q2 2023 Aug 14, 2023	SELL	$0.51 - $1.43 $137,441 - $385,374	-269,493 Reduced 41.84%	374,624 $344,000
Q1 2023 May 15, 2023	BUY	$0.56 - $1.15 $169,673 - $348,436	302,988 Added 88.82%	644,117 $360,000
Q4 2022 Feb 14, 2023	SELL	$0.25 - $0.58 $1,597 - $3,705	-6,389 Reduced 1.84%	341,129 $197,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $92,706 - $142,149	-309,021 Reduced 47.07%	347,518 $110,000
Q2 2022 Oct 27, 2022	SELL	$0.32 - $0.67 $108,536 - $227,247	-339,175 Reduced 34.06%	656,539 $232,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $108,536 - $227,247	-339,175 Reduced 34.06%	656,539 $232,000
Q1 2022 Oct 27, 2022	BUY	$0.72 - $2.93 $244,206 - $993,782	339,175 Added 51.66%	995,714 $714,000
Q1 2022 May 13, 2022	SELL	$0.72 - $2.93 $144,360 - $587,465	-200,500 Reduced 16.76%	995,714 $714,000
Q4 2021 Feb 14, 2022	SELL	$2.26 - $3.34 $626,677 - $926,151	-277,291 Reduced 18.82%	1,196,214 $2.7 Million
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.88 $3.46 Million - $5.72 Million	1,473,505 New	1,473,505 $4.24 Million

Others Institutions Holding AKBA

# of Institutions

189

Shares Held

121M

Call Options Held

267K

Put Options Held

280K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $313M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account